33 results about "Central retinal vein occlusion" patented technology

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile suppresses increases in retinal blood vessel permeability induced by VEGF and therefore can be used as an active component in therapeutic agents or prophylactic agents for a variety of ocular diseases to which VEGF contributes, such as age-related macular degeneration, diabetic retinopathy, macular edema, neovascular maculopathy, retinal vein occlusion, and neovascular glaucoma.

The disclosure provides methods and ophthalmic NSAIDs as adjuvants to VEGF inhibitors useful for treating retinal disorders, including but not limited to wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and branch retinal vein occlusion.

The present invention relates to novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity. These compounds are useful as therapeutic agents for diseases associated with neovascularization, particularly, as therapeutic agents for cancer, rheumatoid arthritis, age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, polypoidal choroidal vasculopathy, diabetic macular edema, plaque psoriasis, atherosclerosis, and the like.

The present invention relates to the use of hydroxycarbamide (HC) for reducing and / or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.

A method for treating retinal vein occlusion involving administering to a patient a pharmacologically effective amount of a compound represented by the following formula (II) or a salt thereof:wherein R1, R2 and R3 are the same or different and represent a hydrogen atom or an alkyl group, or R1 and R3 may be joined together to form a ring having one or more double bonds.

The invention discloses a traditional Chinese medicine for treating central retinal vein obstruction. The traditional Chinese medicine is characterized by being prepared from the following medicinal materials in parts by weight: 8-10 parts of peach seeds, 8-10 parts of safflower, 12-15 parts of angelica, 12-15 parts of rehmannia root, 8-10 parts of Szechuan lovage rhizome, 8-10 parts of red peony root, 5-6 parts of Chinese thorowax root, 8-10 parts of achyranthes root, 8-10 parts of horse-tail club moss, 5-6 parts of platycodon grandiflorum, 2-3 parts of licorice, 12-15 parts of Chinese arborvitae twigs, 8-10 parts of motherwort fruits, 0-30 parts of clematis finetiana and 0-9 parts of straight-flowered corydalis. A preparation method comprises the steps of weighing the medicinal materials, putting the medicinal materials into a container, adding water of which the quantity is 8 times that of the medicinal materials, decocting for 1.5 hours, and filtering; adding water of which the quantity is 6 times that of filter residues into the filter residues, decocting for 1 hour, and filtering; and combining the filtrates, concentrating, drying, and filling capsule shells with the dried mixture. Clinical experiments prove that the traditional Chinese medicine achieves a significant effect of treating the central retinal vein obstruction by selecting the appropriate medicinal materials and the ratio thereof, is safe and does not have toxic or side effect.